Category: by journal

Another unofficial record? Authors walk back arcane blue crab paper — 15 years later

Portunus trituberculatus, courtesy NOAA

If a paper that has never been cited is retracted, will it be missed?

Japanese researchers have retracted an obscure 1996 article in an equally obscure physics journal after concluding — some 15 years later — that their fundamental assertion was mistaken.

The paper, “Uptake and excretion of cobalt in the crustacean Portunus trituberculatus,” in  Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms, purported to show that a form of the element cobalt might be helpful in tracing the growth of Portunus trituberculatus, otherwise known as the blue crab.

That’s the world’s most harvested crab species and a particular favorite in Asia. But don’t confuse it with the Chesapeake Bay blue crab, Callinectes sapidus, of William Warner’s Pulitzer Prize-winning book, Beautiful Swimmers.

The problem with such elemental tracers, it seems, is that crabs moult repeatedly, shedding their shells, along with the elements that build up inside them. According to researchers from the Research Institute for Advanced Science and Technology and the Osaka Prefectural Fisheries Experimental Station, however, a volatile form of cobalt, previously undetected, could be a suitable element for tracing the growth of both crabs and prawns — another important aquaculture species in Asia — over time.

But that turned out to be a (shell)fish tale. Per the retraction notice, which appears in the May 15, 2011 issue of the journal: Continue reading Another unofficial record? Authors walk back arcane blue crab paper — 15 years later

Blood retracts two, including a disputed paper from the Karolinska Institute

The journal Blood has two retractions this month, one of which seems particularly interesting. So let’s deal with the other one first.

The paper, “MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma,” appeared online in October 2010. But according to the retraction notice, the authors

have recently discovered that the cell lines used in their paper were inadvertently misidentified. The cell lines utilized in the paper have now been found to contain the bcr/abl translocation and most likely represent the K562 CML cell line, instead of MMS1 and RPM1 myeloma cell lines. Due to this issue, the relevance of the findings to myeloma and thus, the conclusions of the paper, are not supported by the data. The authors apologize to the readers, reviewers, and editors of Blood for publishing these erroneous data.

That seems straightforward enough, and we couldn’t find any evidence that this problem affected other publications.

The second paper, however, could be more significant. Continue reading Blood retracts two, including a disputed paper from the Karolinska Institute

Traffic violations: Plagiarism leads to retraction of transit modeling paper

Journal editors like to believe they are more than mere traffic cops. But here’s a case that makes us wonder.

Transportation Research Part E: Logistics and Transportation Review — yes, there are parts A-D of this — is retracting a 2009 paper which stole liberally from a 1996 article in a different journal from the same publisher, in this case Elsevier.

According to the notice, which appeared online earlier this year and in the July 2011 issue: Continue reading Traffic violations: Plagiarism leads to retraction of transit modeling paper

Retractile dysfunction? Author says journal yanked paper linking Viagra, Cialis to vision problem after legal threats

The British Journal of Ophthalmology has retracted a 2006 paper which purported to show a link between drugs for erectile dysfunction and a rare form of sudden vision loss called non-arteritic anterior ischaemic optic neuropathy, more commonly known as “Viagra blindness.”

That wouldn’t be terribly interesting, except for this: One of the authors of the paper, a researcher at the University of Alabama named Gerald McGwin Jr., told us that the journal retracted the article because it had become a tool in a lawsuit involving Pfizer, which makes Viagra, and, presumably, men who’d developed blindness after taking the drug:

The article just became too much of a pain in the rear end. It became one of those things where we couldn’t provide all the relevant documentation [to the university, which had to provide records for attorneys]

Ultimately, however, McGwin said that the BJO pulled the plug on the paper.

It was really the journal’s decision to take it out of the literature.

The retraction notice is mute on the reason for the retraction of the blindness paper (and, so far, our requests for comment seem to have fallen on deaf ears). Here’s all it says: Continue reading Retractile dysfunction? Author says journal yanked paper linking Viagra, Cialis to vision problem after legal threats

Feminism & Psychology study of UK birthing classes draws ire, winds up retracted

The debate — in entrenched medical circles, anyway — over whether it’s safe to give birth at home can be fierce. Just last month, for example, Nature reported that a review of the subject in the American Journal of Obstetrics & Gynecology that found home births more dangerous than those in the hospital generated so much controversy that it forced an investigation. Outside reviewers found problems, but the journal didn’t think they rose to the level of a retraction. Critics disagreed.

The same fraught subject came up in a paper published in Feminism & Psychology last year by Mary Horton-Salway and Abigail Locke. The original paper had concluded:

Our analysis suggests that the normativity of medical interventions in labour and childbirth is discursively reproduced in ante-natal classes whilst parental choice is limited by a powerful ‘rhetoric of risk’.

In other words, NCT classes were scaring women into choosing hospital births. But it turns out that conclusion wasn’t actually supported by the findings, which were based on a review of National Childbirth Trust’s classes. That led to a retraction: Continue reading Feminism & Psychology study of UK birthing classes draws ire, winds up retracted

Data fraud at Emory leads to retractions of three cardiology papers

An investigation by Emory University in Atlanta has led to the retractions of three articles containing falsified data, but the ambiguous wording of the notices leaves us wondering if they are implying more than they state.

Two of the papers appeared in the journal Arteriosclerosis, Thrombosis, and Vascular Biology. The notices in ATVB implicate a researcher named Lian Zuo, who worked in Emory’s division of cardiology.

Here’s one: Continue reading Data fraud at Emory leads to retractions of three cardiology papers

More details emerge on ScienceBlogs-National Geographic deal

Yesterday, we reported that National Geographic had bought ScienceBlogs. We’ve now obtained a recording of a conference call between various members of National Geographic senior management, ScienceBlogs management, and ScienceBloggers — aka Sciblings — that adds some details.

What we’ve learned is that Nat Geo plans to assume control of operations, editorial content, and ad sales by June 1 of this year. And while a post from PZ Myers post said “basically, we’ve been bought,” and we had further confirmation last night of the contents of yesterday’s post from someone familiar with the situation, we want to make sure to point out, high up, that one of the first things that SEED CFO and vice president of finance and operation’s Vera Scavcic said on the call was that SEED would maintain ownership: Continue reading More details emerge on ScienceBlogs-National Geographic deal

So who bought ScienceBlogs? Retraction Watch exclusive: National Geographic

This afternoon, PZ Myers, of the wildly popular Pharyngula blog on ScienceBlogs, started a post with a few lines that set science writers on Twitter abuzz:

I have news. Scienceblogs is going to be folded into a new organization sometime soon — basically, we’ve been bought. I can’t discuss all of the details just yet, but let’s just say it is a prestigious national magazine with a healthy bottom line that will do us a lot of good.

Retraction Watch has learned, from a source familiar with the negotiations, that the buyer is National Geographic. We don’t have any details at this point, and Nat Geo has not returned a request for comment [see update at end], but we are confident in reporting this.

Readers may recall PepsiGate, Continue reading So who bought ScienceBlogs? Retraction Watch exclusive: National Geographic

Science publishes replication of Marc Hauser study, says results hold up

There has been some news over the past few weeks about Marc Hauser, the Harvard psychologist found guilty of misconduct by the university last year. First, because Harvard had listed him in a course catalog, The Crimson said that he might be teaching again, following a ban. But that turned out not to be the case, as The Boston Globe reported.

Today, Science lifted the embargo on a paper by Hauser and Justin Wood, now of the University of Southern California, showing that results published in the journal in 2007 — and later questioned — have held up. The abstract: Continue reading Science publishes replication of Marc Hauser study, says results hold up

Update: After unexplained delay, Cell Cycle retracts paper related to work that formed the basis of anti-cancer company

In December, we reported on the retraction of a paper in the Proceedings of the National Academy of Sciences on a potential treatment for breast cancer. We later found out that the retracted research was part of the basis of a company that had an initial public offering a few weeks later. How the company dealt with the news of the retraction made for an interesting follow-up, and speaks well of the principles of the principals.

Here’s another follow-up. The retraction notice has now appeared of a related review in Cell Cycle that we reported would be withdrawn. Here’s the text: Continue reading Update: After unexplained delay, Cell Cycle retracts paper related to work that formed the basis of anti-cancer company